Výsledky vyhledávání - "Belilovski Rozenblum, A."

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

Autor: Lior Soussan-Gutman, Nir Peled, Smadar Laufer-Geva, R. Grinberg, Anna Belilovski Rozenblum, Richard B. Lanman, Alona Zer, Tal Twito, Elizabeth Dudnik, Ofer Rotem, Laila C. Roisman, Maya Ilouze, Addie Dvir

Publikováno v: Journal of Thoracic Oncology. 13:1705-1716

Introduction Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected genomic alterations (GAs) have been shown to predict targeted therapy response,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73377ea25aea0e4debe66bae3f389a1b
https://doi.org/10.1016/j.jtho.2018.07.101

Zobrazit plný text záznamu

Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer

Autor: S. Geva, Maya Ilouze, Elizabeth Dudnik, Lior Soussan-Gutman, Anna Belilovski Rozenblum, Nir Peled, Addie Dvir

Publikováno v: Journal of Thoracic Oncology. 12:258-268

Introduction Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor tyrosine kinase gene ( ALK ) testing. Next-generation sequencing (NGS) reveals more

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec593690f3c4cfdd2d247032515e0f40
https://doi.org/10.1016/j.jtho.2016.10.021

Zobrazit plný text záznamu

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

Autor: Elizabeth Dudnik, Maya Ilouze, Anna Belilovski Rozenblum, Alona Zer, Nir Peled, Laila C. Roisman, Anna May Suidan

Publikováno v: Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)

Lung cancer (LC) is the leading cause of cancer mortality worldwide. Despite advances in the treatment strategy, including surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy, 5-year survival is estimated as 9% to 20%.1,2 During

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edeb46a18aaf0014c2e91facc3321585
http://europepmc.org/articles/PMC6550091

Zobrazit plný text záznamu

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)

Autor: Anna Belilovski Rozenblum, Ludmila Fridel, Alona Zer, Ahuva Grubstein, Nir Peled, S. Geva, Elizabeth Dudnik, Laila C. Roisman, Aaron M. Allen, Tzippy Shochat, Elias Bshara, Maya Ilouze, Ofer Rotem

Publikováno v: Lung cancer (Amsterdam, Netherlands). 124

Efficacy of immune check-point inhibitors (ICPi) in NSCLC with rare targetable drivers (RTDs) is largely unknown.Consecutive patients with NSCLC and RTDs (non-EGFR/ALK, n-82) were selected from the Davidoff Cancer Center database. ORR, PFS, OS with I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2222034ea9e058f84beb64ca122877e0
https://pubmed.ncbi.nlm.nih.gov/30268448

Zobrazit plný text záznamu

Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study

Autor: Shlomit Yust-Katz, Ilan Shelef, Hovav Nechushtan, Elizabeth Dudnik, Laila C. Roisman, E. Inbar, Roni Gillis, Anna Belilovski Rozenblum, I. Goldshtien, Ofer Rotem, Alona Zer, Nir Peled, L. Chen

Publikováno v: Annals of Oncology. 30:ix177-ix178

Background Osimertinib is an EGFR TKI selective for both EGFR TKI sensitizing and Thr790Met resistance mutations. While intracranial activity of osimertinib has been observed in patient subgroups within larger trials, a study focusing exclusively on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f3a80434ca054d916fb37931633b492
https://doi.org/10.1093/annonc/mdz437.054

Zobrazit plný text záznamu

[THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER]

Autor: Anna, Belilovski Rozenblum, Maya, Ilouze, Elizabeth, Dudnik, Lior, Soussan-Gutman, Addie, Dvir, Nir, Peled

Publikováno v: Harefuah. 156(11)

In the last decade, important advances in understanding the lung cancer cellular signal pathways have led to the designing of targeted drugs that significantly prolong survival. Recent data shows that 64% of lung adenocarcinomas harbor at least one a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2bae9086f257051be021be0be0c84794
https://pubmed.ncbi.nlm.nih.gov/29198084

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání